Anixa Biosciences announced that the Mexican Institute of Industrial Property (IMPI) granted Patent 432748 on April 29, 2026. The patent protects the company’s α‑lactalbumin‑based breast‑cancer vaccine, a preventive immunotherapy that targets a protein expressed in certain aggressive breast cancers.
The Mexican patent extends Anixa’s intellectual‑property protection into a market with a high incidence of triple‑negative breast cancer and late‑stage diagnoses. It complements the company’s existing patents in the United States, China, Mexico, and Korea, all of which are scheduled to expire in the 2040s. By securing protection in Mexico, Anixa positions itself to pursue global commercialization and potential licensing deals with large pharmaceutical partners.
"This newly issued patent continues the broad international recognition of the novelty and potential of our breast cancer vaccine," said Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences. "As we continue clinical development in the U.S., our growing international patent estate further strengthens our ability to pursue global opportunities and potentially partner with larger pharmaceutical companies for worldwide commercialization."
Anixa is a pre‑revenue company that reported a net loss in Q1 2026, with earnings per share of –$0.08 versus an estimate of –$0.10, a beat of $0.02. The company’s cash, cash equivalents, and short‑term investments totaled $14.202 million as of January 31, 2026, which management believes will fund operations for at least the next twelve months.
The patent milestone supports Anixa’s partner‑driven development strategy, allowing the company to monetize early‑stage assets without building commercial infrastructure. The breast‑cancer vaccine program is a cornerstone of the company’s strategy to develop next‑generation preventive immunotherapies, and the company is preparing for a Phase 2 trial following successful Phase 1 data that met all primary endpoints and demonstrated a favorable tolerability profile at the maximum tolerated dose.
The expanded IP estate, combined with ongoing clinical progress, positions Anixa to advance its vaccine into future trials and to negotiate licensing agreements that could accelerate global commercialization of a potentially game‑changing preventive therapy for breast cancer.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.